- the ability to comply with regulatory requirements applicable to the
manufacture and marketing of DRAXIS' products;
- DRAXIS' ability to obtain and enforce effective patents;
- the non-infringement of third party patents or proprietary rights by
DRAXIS and its products;
- factors beyond DRAXIS' control that could cause interruptions in
operations in its single manufacturing facility (including, without
limitation, material equipment breakdowns);
- reimbursement policies related to health care;
- the establishment and maintenance of strategic collaborative and
commercial relationships;
- DRAXIS' dependence on a small number of key customers;
- the disclosure of confidential information by DRAXIS' collaborators,
employees or consultants;
- the preservation of healthy working relationships with DRAXIS' union
and employees;
- DRAXIS' ability to grow the business;
- the fluctuation of DRAXIS' financial results and exchange and
interest rate fluctuations;
- the adaptation to changing technologies;
- the loss of key personnel;
- the avoidance of product liability claims;
- the loss incurred if current lawsuits against DRAXIS succeed;
- the volatility of the price of DRAXIS' common shares;
- market acceptance of DRAXIS' products;
- factors described under "Outlook" in DRAXIS' MD&A for the most recent
quarter; and
- the risks described in "Item 3. Key Information - Risk Factors" in
the Annual Report Form 20-F filed by DRAXIS with the United States
Securities and Exchange Commission and which is also filed as
DRAXIS' Annual Information Form with Canadian securities regulators.
For additional information with respect to certain of these and other
factors, and rel
'/>"/>
| SOURCE DRAXIS Health Inc. Copyright©2008 PR Newswire. All rights reserved |